Company news
Cynata Therapeutics Limited news in 2018
Cynata Therapeutics Limited's news releases, calls and decks from 2018, newest first.
Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD
December 18, 2018
Cynata Completes Clinical Study Report in GvHD
December 17, 2018
NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis
December 13, 2018
NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
December 12, 2018
Cynata Receives $1.3m R&D Tax Incentive Refund
November 18, 2018
CYP Receives Notice of Allowance from European Patent Office
November 6, 2018
September 2018 Quarterly Report
October 23, 2018
Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
October 18, 2018
MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
October 17, 2018
Cynata MSCs Ameliorate CRS in Preclinical Study
September 19, 2018
Cynata Advances to Official Meeting with Japanese PMDA
September 2, 2018
Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
August 29, 2018
Appendix 4E & Financial Statements
August 22, 2018
Cymerus MSCs improve cardiac recovery in preclinical study
July 30, 2018
June 2018 Quarterly Report
July 11, 2018
Cynata Enters Development Partnership with RCSI
July 1, 2018
Product Development Program Update & Investor Presentation
June 25, 2018
Positive 28-day Clinical Trial Data in Cohort B
June 20, 2018
Research Collaboration with UNSW for Coronary Artery Disease
June 18, 2018
Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
June 11, 2018
Cynatas MSCs Effective in Model of Diabetic Wounds
May 30, 2018
$5.2m placement of shares to Fidelity International
May 29, 2018
Enrolment Completed in Cynatas Phase 1 Clinical Trial
May 23, 2018
Notice of Allowance from EPO for Patent Application
May 7, 2018
March 2018 Quarterly Report
April 27, 2018
CYP Completes Patent Application related to CAR-T Therapy
April 19, 2018
Further US Patent Granted for Cynata Cymerus Technology
April 10, 2018
FDA Grants Orphan Drug Designation to Cyanta for CYP-001
March 27, 2018
Excellent Data from Final Preliminary Evaluation Period
February 26, 2018
Cynata Engineered MSC Study Review Reveals Promising Results
February 4, 2018
December 2017 Quarterly Report
January 30, 2018
Cynata Treats First Patient in Cohort B
January 23, 2018
Cyanta & Celularity Inc Execute MOU
January 22, 2018
Encouraging Early Data-Cynata Clinical Trial Proceeds
January 21, 2018
Decks in 2018
- Shareholder Meeting (November 2018)
Shareholder meeting · 45 slides · Nov 15, 2018
- Investor Presentation (November 2018)
Investor deck · 45 slides · Nov 1, 2018
- Investor Presentation (June 2018)
Investor deck · 26 slides · Jun 26, 2018